SXTPNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTPW

60 DEGREES PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.83−0.03 (-3.29%)

Close on Oct 19, 2026

Market cap: $2.20M
P/E (TTM): –
Dividend yield: –

60 DEGREES PHARMACEUTICALS, INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	1.01	0.61	0.25	0.22
Cost of Revenue	0.78	0.38	0.47	0.43
Gross Profit	0.22	0.22	-0.22	-0.21
Research & Development	2.11	4.99	0.69	0.53
General & Administrative	6.28	5.03	4.24	1.30
Operating Expenses	8.39	10	4.93	1.83
Operating Income	-7.76	-9.72	-5.15	-1.75
Interest Expense	0.01	0.01	2.29	3.99
Other Non-Operating Income	0.39	1.76	-0.08	-0.04
Pretax Income	-7.37	-7.96	-3.81	-6.18
Income Tax Expense	0	0	0.00	0.00
Income from Continuing Operations	–	–	-0.22	0.08
Net Income incl. Noncontrolling Interests	-7.37	-7.96	-3.81	-6.18
Minority Interest in Earnings	0.00	-0.01	-0.05	0.00
Net Income	-7.37	-7.95	-3.77	-6.18
Preferred Dividends	1.21	0.70	–	–
Net Income to Common	-7.86	-8.43	-3.92	-6.18
EPS (Basic)(per share)	-11.73	-74.17	-236.72	-626.40
EPS (Diluted)(per share)	-11.73	-74.17	-236.72	-626.40
Shares Outstanding (Basic, Weighted)(shares)	0.67	0.11	0.02	0.01
Shares Outstanding (Diluted, Weighted)(shares)	0.67	0.11	0.02	0.01
EBITDA	-7.72	-9.70	-5.13	–
Net Interest Income	–	–	1.34	-4.43

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 19.4%
Operating margin: -774.9%
Net margin: -729.9%
Return on equity, FY2025: -196.4%

Financial strength

Current ratio: 2.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 63.7%

Valuation

P/E ratio: –
Price to sales: 1.98
Price to book: 0.84
Dividend yield: –